BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Corxel Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Corxel Pharmaceuticals's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06736574-593@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Omecamtiv mecarbil: Phase 3 readout est. (NCT06736574)
DESCRIPTION:Omecamtiv mecarbil\, phase 3\, Heart Failure.\nStudy: Study Wit
 h Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Seve
 rely Reduced Ejection Fraction\nEstimated primary completion: September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/omecamtiv-mecarbi
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 736574
URL:https://assetmemo.bio/drug/omecamtiv-mecarbil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
